IRIS
TETI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.267
AS - Asia 2.512
EU - Europa 1.836
Continente sconosciuto - Info sul continente non disponibili 372
SA - Sud America 347
AF - Africa 51
OC - Oceania 5
Totale 13.390
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.128
SG - Singapore 1.051
IT - Italia 642
CN - Cina 401
RU - Federazione Russa 271
BR - Brasile 270
HK - Hong Kong 231
VN - Vietnam 220
KR - Corea 194
DE - Germania 179
BD - Bangladesh 149
IE - Irlanda 136
GB - Regno Unito 102
SE - Svezia 88
JP - Giappone 79
FR - Francia 78
CA - Canada 72
FI - Finlandia 63
IN - India 59
NL - Olanda 58
UA - Ucraina 56
PL - Polonia 36
AT - Austria 32
AR - Argentina 29
MX - Messico 28
ES - Italia 24
ID - Indonesia 19
IQ - Iraq 19
ZA - Sudafrica 18
TR - Turchia 17
BE - Belgio 14
EC - Ecuador 14
JM - Giamaica 14
VE - Venezuela 11
CZ - Repubblica Ceca 10
PK - Pakistan 10
GR - Grecia 9
CH - Svizzera 8
CO - Colombia 8
CR - Costa Rica 8
PH - Filippine 8
MA - Marocco 7
EG - Egitto 6
IL - Israele 6
KG - Kirghizistan 6
UZ - Uzbekistan 6
IR - Iran 5
LT - Lituania 5
MY - Malesia 5
PY - Paraguay 5
SA - Arabia Saudita 5
TT - Trinidad e Tobago 5
AU - Australia 4
CL - Cile 4
KE - Kenya 4
LV - Lettonia 4
TN - Tunisia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
HN - Honduras 3
JO - Giordania 3
OM - Oman 3
PE - Perù 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
AZ - Azerbaigian 2
BB - Barbados 2
DK - Danimarca 2
DZ - Algeria 2
KH - Cambogia 2
KZ - Kazakistan 2
MK - Macedonia 2
NG - Nigeria 2
NP - Nepal 2
PR - Porto Rico 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
CG - Congo 1
CM - Camerun 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GT - Guatemala 1
HR - Croazia 1
LC - Santa Lucia 1
ML - Mali 1
NZ - Nuova Zelanda 1
PA - Panama 1
SC - Seychelles 1
Totale 13.019
Salva come PNG Salva come JPEG
Città #
Wilmington 1.673
Houston 1.064
Woodbridge 994
Singapore 604
San Jose 440
Ashburn 388
Chandler 340
Hong Kong 226
Fairfield 213
Rome 208
Council Bluffs 181
New York 170
Beijing 143
Los Angeles 134
Ann Arbor 115
Dublin 109
Santa Clara 90
Seattle 85
Ho Chi Minh City 83
Tokyo 76
The Dalles 74
Cambridge 73
Medford 68
Munich 55
Buffalo 54
Dallas 54
Dearborn 52
Hanoi 51
Moscow 44
Milan 42
Denver 40
Orem 38
Helsinki 33
Chicago 31
Lawrence 31
Nuremberg 31
São Paulo 31
Lauterbourg 28
London 28
San Diego 28
Frankfurt am Main 22
Montreal 22
Engelhard 21
Toronto 21
Atlanta 19
North Bergen 19
Palo Alto 19
Phoenix 19
Brooklyn 18
Naples 18
Jacksonville 17
Warsaw 17
Amsterdam 15
Lappeenranta 15
Chennai 14
Boardman 13
Brussels 13
Manchester 13
Menlo Park 13
Stockholm 13
Vienna 13
Washington 13
Ciampino 12
Colorado Springs 12
Mexico City 12
Mumbai 11
Guangzhou 10
Haiphong 10
Jakarta 10
Johannesburg 10
Redondo Beach 10
Shanghai 10
Zhengzhou 10
Boston 9
Kingston 9
Seoul 9
Hefei 8
Paris 8
Philadelphia 8
Rio de Janeiro 8
San Francisco 8
St Louis 8
Da Nang 7
Lahore 7
Miami 7
Nanjing 7
Palermo 7
Queens 7
San José 7
Tampa 7
Turku 7
Bari 6
Bologna 6
Cedarhurst 6
Chandigarh 6
Elk Grove Village 6
Poplar 6
St. George 6
Athens 5
Baghdad 5
Totale 8.896
Salva come PNG Salva come JPEG
Nome #
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 506
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 490
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 481
Cortical sources of resting state electroencephalographic rhythms probe brain function in naïve HIV individuals 452
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 434
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 428
Abnormal cortical sources of resting state electroencephalographic rhythms in single treatment-naïve HIV individuals: A statistical z-score index 410
Brain and cognitive functions in two groups of naïve HIV patients selected for a different plan of antiretroviral therapy: A qEEG study 380
Corrigendum to “Brain and cognitive functions in two groups of naïve HIV patients selected for a different plan of antiretroviral therapy: A qEEG study” [Clin. Neurophysiol. 127 (2016) 3455–3469]((S1388245716305089)(10.1016/j.clinph.2016.09.001)) 368
Antiretroviral therapy affects the z-score index of deviant cortical EEG rhythms in naïve HIV individuals 362
Cerebral Multishell Diffusion Imaging Parameters are Associated with Blood Biomarkers of Disease Severity in HIV Infection 341
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 323
Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis 321
Corrigendum to “Abnormal cortical sources of resting state electroencephalographic rhythms in single treatment-naïve HIV individuals: A statistical z-score index” [Clin. Neurophysiol. 127 (2016) 1803–1812] (S138824571501559X) (10.1016/j.clinph.2015.12.007)) 313
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy 307
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report 295
Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: A case report 262
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir 251
Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients 201
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab 192
Cryptic HBV replicative activity is frequently revealed in anti-HBC-positive/hbsag-negative patients with HIV infection by highly sensitive molecular assays, and can be predicted by integrating classical and novel serological HBV markers 191
Frequency of atypical mutations in the spike glycoprotein in SARS-CoV-2 circulating from July 2020 to July 2022 in central Italy: a refined analysis by Next Generation Sequencing 170
Long-term SARS-CoV-2 infection associated with viral dissemination in different body fluids Including bile in two patients with acute cholecystitis 167
Disruption of brain network organization in patients with human immunodeficiency virus (HIV) infection 165
Multishell diffusion MRI reveals whole-brain white matter changes in HIV 160
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 157
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications 156
T-cell responses to SARS-CoV-2 in Multiple Sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-Spike antibody titers 155
Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b 150
Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in {SARS}-{CoV}-2 infected patients: a single center study 148
In patients with severe COVID-19, the profound decrease in the peripheral Bblood T-cell subsets is correlated with an increase of QuantiFERON-TB Gold Plus indeterminate rates and reflecting a reduced interferon-gamma production 141
Persistence of circulating CD169+monocytes and HLA-DR downregulation underline the immune response impairment in PASC individuals: the potential contribution of different COVID-19 pandemic waves 135
Functional brain network reorganization in HIV infection 127
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replication 124
Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection 120
Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients 118
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing. 117
Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice 117
Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study 116
Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience 111
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort 110
The Impact of Viral and Bacterial Co-Infections and Home Antibiotic Treatment in SARS-CoV-2 Hospitalized Patients at the Policlinico Tor Vergata Hospital, Rome, Italy 110
Compartmental models for diffusion weighted MRI reveal widespread brain changes in HIV-infected patients 110
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 109
HIV DNA viral reservoirs in blood and gut-associated lymphoid tissues (GALT): Implications of switch from triple antiretroviral therapy (ART) to 2-drug dolutegravir/lamivudine regimens 107
HUMAN ENDOGENOUS RETROVIRUSES EXPRESSION CORRELATES WITH HIV RESERVOIR, LYMPHOCYTES ACTIVATION AND LOW CD4 COUNT IN VIROLOGICALLY SUPPRESSED PATIENTS 104
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 104
An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein. 102
HDV replicative activity parallels the production of the three HBsAg forms (Large, Middle and Small HBsAg) and its pathogenetic impact is exacerbated by concomitant HBV replication 99
Higher levels of three HBsAg forms (Large, Middle and Small HBsAg) are associated with HDV replication and with the degree of disease and liver damage. 97
HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA After Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort 94
The evolving landscape of COVID-19: Factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance 92
Hepatitis B-related hepatic flare during immune reconstitution syndrome after antiretroviral treatment initiation in an HBV surface antigen-positive patient with HIV: viroimmunological and histological characterization 89
Chronic HDV coinfection (CHD) is characterized by a different HBsAg isoforms composition respect to HBV mono-infection with higher middle- and large-HBs levels paralleling the replicative and cytolytic activity of HDV. 89
Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Acinetobacter baumannii Infections 88
A peculiar HBsAg isoforms composition characterizes chronic HDV coinfection respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 88
Chronic HDV coinfection (CHD) is characterized by a more elevated production of Middle and Large HBsAg than HBV mono-infection, that parallels HDV replicative and cytolytic activity. 85
Total HIV DNA and cell-associated HIV RNA viral reservoirs in PBMCs and GALT in patients on triple-ART and switching to dual-ART regimens. 80
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 80
HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch 78
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 76
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 76
Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine 75
The transactivation of endogenous retroviruses correlates with HIV reservoir, lymphocytes activation and low CD4 count in virologically suppressed patients 74
null 74
Chronic HDV coinfection is characterized by a peculiar HBsAg isoforms composition respect to HBV mono-infection, with higher middle-/large-HBs levels paralleling HDV activity. 73
The transactivation of human endogenous retroviruses is associated with HIV-1 reservoir, lymphocyte activation and low CD4 count in virologically suppressed PLWH 70
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program 70
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 67
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 66
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 64
COVID ‐19 and Liver Injury, Beyond the First Pandemic Waves: Clinical and Immune‐Virological Features 63
Whole-brain white matter network reorganization in HIV 62
Continuum of care nella popolazione tossicodipendente nell’ambito dell’infezione da HCV: dati di Real Life 53
COVID-19 and influenza vaccination among adults stably engaged in HIV care 51
Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers 49
Intrahepatic HDV Activity Is Fueled By Integrated HBV DNA-Derived HBs Independently From CccDNA Size 48
A high degree of genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity. 47
HDV persistence acts independently from HBV reservoir extent and is sustained by HBsAg production mainly derived from integrated HBV-DNA 47
Chronic HDV coinfection is characterized by a more elevated production of all three HBsAg isoforms compared to HBV mono-infection, that parallels HDV replicative and cytolytic activity. 45
Clinical and laboratory parameters correlated to HDV undetectability after 48 weeks of bulevirtide 40
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 37
Malagnino Valutazione della risposta biochimica e virologica dopo 72 settimane di terapia con Bulevirtide ed analisi della cinetica virale intraepatica in una coorte di pazienti affetti da epatite delta. 36
HBV integration can sustain intrahepatic HDV activity and can modulate HBV pathogenetic potential. 34
An increased genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity 34
Intra-hepatic HDV replicative activity can be sustained by HBsAg production from HBV-DNA integration and can modulate virological response to bulevirtide 29
HDV sub-genotype 1 is characterized by increased genetic variability, which can promote the emergence of divergent genetic pathways that modulate HDV replicative potential and cytolytic activity. 29
Chronic HDV Infection Shows Higher HBsAg Isoform Levels than HBV Infection, Paralleling HDV Replicative Activity 24
Totale 13.390
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.356
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022419 0 0 0 38 2 64 29 52 68 42 24 100
2022/2023795 76 85 75 101 73 145 48 62 78 2 37 13
2023/2024437 50 9 44 29 28 97 15 14 5 76 7 63
2024/20251.737 75 245 179 103 37 123 203 143 166 170 156 137
2025/20263.818 376 152 333 342 340 142 490 419 476 324 231 193
2026/20271.361 248 211 602 300 0 0 0 0 0 0 0 0
Totale 13.390